AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.
Funding Rounds (5) - $26.1MUpdate
Current Team (1)Update
|Jan 13, 2010||eisai.co.jp - Eisai acquired AkaRx|
|Jan 6, 2010||PRNewswire All - Eisai Completes Acquisition of AkaRx, Inc. and Continues Development of AKR-501 for Thrombocytopenia|
Mack Centre IV
Paramus, NJ 07652